IPP Bureau
Biocon Biologics’ sponsored report suggests ways to increase adoption of Biosimilars in poor countries
By IPP Bureau - October 09, 2024
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Aurigene Oncology gets positive results of Phase 1 study for CAR-T cell therapy for multiple myeloma
By IPP Bureau - October 09, 2024
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
DKSH partners with R-Biomeds to bring oncology and thyroid treatments to Cambodia
By IPP Bureau - October 09, 2024
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
Vestige Marketing launches two innovative products
By IPP Bureau - October 09, 2024
Biotin Sublingual Spray and Melatonin Sublingual Spray to help consumers tackle health issues that come with today’s fast-paced life
Jubilant Ingrevia becomes only Indian company to join WEF’s Global Lighthouse Network
By IPP Bureau - October 09, 2024
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
Aster implements India’s first IOeRT for cancer care
By IPP Bureau - October 09, 2024
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals
By IPP Bureau - October 09, 2024
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
FDA grants fast track designation to Wockhardt's novel antibiotic WCK 6777
By IPP Bureau - October 08, 2024
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Davaindia accelerates expansion with 1,165 operational stores
By IPP Bureau - October 08, 2024
Strategic focus on COCO-model with a nationwide reach of 501 stores
AstraZeneca, CSPC Pharmaceutical agree for a pre-clinical novel lipid-lowering therapy
By IPP Bureau - October 08, 2024
CSPC will receive an upfront payment of $100 million from AstraZeneca
Lupin and Scope sign agreement for commercialization of Optase in Mexico
By IPP Bureau - October 08, 2024
The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions
Lupin acquires nine brands of Medical Nutritional Institute in South Africa
By IPP Bureau - October 06, 2024
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Calquence granted priority review in US for patients with untreated mantle cell lymphoma
By IPP Bureau - October 06, 2024
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories
By IPP Bureau - October 06, 2024
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Dr. Reddy’s Laboratories Switzerland incorporates a subsidiary in Denmark
By IPP Bureau - October 06, 2024
he company will focus on production of any pharmaceutical and biotechnological products
